A new stem cell therapy, CALEC, has demonstrated a 92% success rate in regenerating corneas and restoring vision. This breakthrough procedure is still experimental but shows immense promise for those with previously untreatable eye injuries.

An expanded clinical trial that tested a groundbreaking, experimental stem cell treatment for blinding cornea injuries found the treatment was feasible and safe in 14 patients who were treated and followed for 18 months, and there was a high proportion of complete or partial success. The results of this new phase 1/2 trial published March 4, 2025 in Nature Communications.

<em>Nature Communications</em> is an open-access, peer-reviewed journal that publishes high-quality research from all areas of the natural sciences, including physics, chemistry, Earth sciences, and biology. The journal is part of the Nature Publishing Group and was launched in 2010. “Nature Communications” aims to facilitate the rapid dissemination of important research findings and to foster multidisciplinary collaboration and communication among scientists.